Atea Pharmaceuticals (AVIR) Options Chain & Prices $5.10 -0.15 (-2.84%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Options Chain Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR Put and Call Options List 12/17/2027 1/15/2027 10/16/2026 9/18/2026 8/21/2026 Options Date Put and Call Options Put Options Call Options Options Type All In The Money Out of The Money Moneyness With Volume Without Volume All Volume Strike Price Min Strike Price Max Export ExpiresStrike PriceClose PricePut/CallVolumeVolume AskVolume BidOpen InterestImplied VolatilityDeltaTrades8/21/2026$5.00$0.632Call1 - - 183(+0)124.01% (-4.15%)0.6295021End-of-day options data provided by Trade Alert and Intrinio. Related Companies and Tools Related Companies Harrow Options Data Xeris Biopharma Options Data Eton Pharmaceuticals Options Data Ardelyx Options Data Collegium Pharmaceutical Options Data Pacira BioSciences Options Data Cronos Group Options Data Eyepoint Pharmaceuticals Options Data Amphastar Pharmaceuticals Options Data Theravance Biopharma Options Data Options Chain Tools Short Interest TrackerShort Interest IncreasesShort Interest DecreasesUnusual Call VolumeUnusual Put Volume This page (NASDAQ:AVIR) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersThis Junior Silver Explorer Is Closing In on Its Biggest CatalystA past-producing Nevada silver project holds a historical 36 million ounce silver-equivalent resource, plus mo...Wall Street Logic | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredBuy this stock tomorrowA new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...Chaikin Analytics | SponsoredFDA Clears This Under-$5 Biotech for Phase 2 Clinical TrialA NASDAQ-listed biotech just cleared a major FDA milestone. Its lead therapy, Lucid-MS, has been cleared for P...The Tomorrow Investor | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredSpaceX is NOT the #1 IPO of 2026A lesser known AI company is growing faster than both SpaceX and OpenAI. Its coding business reportedly grew f...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
